Launching its first European therapy centre in the Netherlands in early 2021, Field Trip Health is providing psychedelic healing experiences using truffles.
Leafy Tunnel’s USD$30m (~£22.38m) fund focuses on global psychedelics opportunities alongside European medical cannabis opportunities.
Dalriada will be leveraging atai Life Science’s newly launched Invyxis platform to establish and rapidly advance a pipeline of new chemical entities (NCEs) in mental health.
The Multidisciplinary Association for Psychedelic Studies (MAPS) has been granted the Innovation Passport for MDMA as an adjunct to therapy for post-traumatic stress disorder (PTSD).
The training of psychotherapists has begun for a clinical trial that will examine 5-MeO-DMT assisted psychotherapy in treatment-resistant depression (TRD).
Mydecine has signed a Letter of Intent (LOI) with The Newly Institute to provide psychedelic-assisted psychotherapy to patients for Health Canada’s Special Access Program.
A new MoU will explore a partnership to utilise MDMA-assisted psychotherapy for the treatment of Alcohol Use Disorder (AUD) in Europe.
Signatures for an Italian campaign calling for the decriminalisation of psychotropic substance cultivation have now been verified by officials.
Psychedelics manufacturer Psygen has received the dealer’s license for LSD, MDMA, psilocybin, psilocin, DMT, 2C-B and mescaline.
Numinus Wellness received final approval from the Toronto Stock Exchange to graduate its listing to the TSX from the TSX-Venture Exchange.
